Equillium sees filing u.s. ind for itolizumab for covid-19, initiating global phase 3 clinical study in q4

Equillium announces successful completion of fda pre-ind meeting enabling advancement of itolizumab into a potential registration study as a treatment for hospitalized covid-19 patients.equillium inc - anticipates filing a u.s. ind for itolizumab for covid-19 and initiating a global phase 3 clinical study in q4.equillium inc - anticipates beginning formal applications to governmental agencies for funding support of clinical study.equillium inc - fda indicated proposed study, if it meets primary & key secondary endpoints, may be sufficient for a bla submission.
EQ Ratings Summary
EQ Quant Ranking